Loading
A phase 3 trial of Fulvestrant, Gedatolisib, Palbociclib and Ribociclib in HR-positive / HER2-negative breast cancer, run by Celcuity Inc, now recruiting.
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) is a phase 3 interventional study registered as NCT06757634 by Celcuity Inc, with 1180 participants planned, started 2025-07-24 and due to reach its primary completion in 2029-03-31. Interventions recorded: Arm A: Gedatolisib + Palbociclib + Fulvestrant, Arm B: Ribociclib + Fulvestrant, Arm C: Gedatolisib + Palbociclib + Letrozole and Arm D: Ribociclib + Letrozole.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Celcuity, Gedatolisib, Palbociclib, Fulvestrant and the tag pipeline.
Shares Ribociclib, Palbociclib, CDK4/6 inhibitors, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Ribociclib, Palbociclib, Fulvestrant, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Ribociclib, Fulvestrant, CDK4/6 inhibitors, Small-molecule kinase inhibitors and the tag pipeline.
Shares Ribociclib, Palbociclib, Fulvestrant, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Ribociclib, Palbociclib, Fulvestrant, Small-molecule kinase inhibitors and the tag pipeline.
Shares Palbociclib, Fulvestrant, CDK4/6 inhibitors and the tag pipeline.
Shares Palbociclib, Fulvestrant, HR-positive / HER2-negative breast cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/